Covid antiviral pill can halve risk of hospitalisation

Covid antiviral pill

An experimental Covid antiviral pill cuts the risk of hospitalisation or death by about half, interim clinical trial results suggest. The tablet – molnupiravir – was given twice a day to patients recently diagnosed with the disease.

An analysis of 775 patients in the study found:

  • 7.3% of those given molnupiravir were hospitalised
  • that compares with 14.1% of patients who were given a placebo or dummy pill
  • there were no deaths in the molnupiravir group, but eight patients who were given a placebo in the trial later died of Covid